Clinical Trial: A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530367) titled 'A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis' on April 08.

Brief Summary: Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Palmoplantar Pustulosis (PPP)

Intervention: DRUG: To...